Current partners

PartneringVernalis has a number of potentially high-value drug development programmes in partnership at present. These include two candidates in imuno-oncology, three candidates in oncology and an additional one in asthma and allergic rhinitis.

Current partnered programmes are as follows:

Item Indications Partner Status
CPI-444 Imuno-oncology Corvus Phase I Results (undisclosed)
V2006 (Vipadenant) Imuno-oncology Redox/Juno Partner Newsflow (undisclosed)
Bcl-2 Cancer Servier / Novartis Phase I Results (undisclosed)
Mcl-1 Cancer Servier / Novartis Phase I Results (undisclosed)
CHR-2797 (Tosedostat) Cancer CTI BioPharma Partner Newsflow
RPL554 Asthma / Allergic rhinitis Verona Pharma Phase IIb Study Results
       

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch